Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4911-4916

  Tfayli, Arafat ^a   Holter, Jennifer ^a   Bova, Abby ^a   Venkatappa, Siddhartha ^b   Bullock, Susie ^a   Dooley, William ^a   Ozer, Howard ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b Oncology Hematology Group of South Florida   (United States)

Author keywords

Breast cancer; Docetaxel; Epirubicin; Neoadjuvant therapy

Indexed keywords

AROMATASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HORMONAL THERAPY; HUMAN; MULTIPLE ORGAN FAILURE; MYALGIA; NAIL; NAUSEA; NEUROPATHY; NEUTROPENIA; ORAL MUCOSAL DISEASE; PREMENOPAUSE; PRIORITY JOURNAL; RASH; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS;

EID: 33845949327     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer Statistics, 2000. CA Cancer J Clin 50: 7, 2000.
2. Ries LAG, Kosary CL, Hankey BF et al: SEER Cancer Statistics Review. Bethesda MD (eds.). National Cancer Institute, pp. 1973-1996, 1999
3. Henderson IC: Chemotherapy for metastatic disease. In: Breast Diseases (ed 2). Harris JR, Hellman S and Henderson IC et al (eds.). Philadelphia, PA, Lippincott, pp. 604-664, 1991.
4. Cummings FJ, Gelman R and Horton J: Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors. J Clin Oncol 3: 932-940, 1985.
5. Nabholtz JM, Mackey JR, Smylie M et al: Phase II study of Docetaxel, Doxorubicin and Cyclophosphamide as first line chemotherapy for metastatic breast cancer. J Clin Oncol 19: 314-321, 2001.
6. Trudeau M and Pagani O: Epirubicin in combination with the taxanes. Seminars in oncology 28(4 Suppl 12): 41-50, 2001.
7. Fossati R, Confalonieri C, Torri V et al: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460, 1998.
8. Gianni L, Munzone E, Capri G et al: Paclitaxel in metastatic breast cancer: a trial of two doses by 3 hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169-1175, 1995.
9. Nabholtz JM, Gelmon K, Bontenbal M et al: Multicenter, randomized comparative study of two doses of Paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-867, 1996.
10. Seidman AD, Barrett S, Hudis C et al: Three hour Taxol infusion as intitial and as salvage chemotherapy of metastatic breast cancer. Proc Am Soc Clin Oncol 13: A65, 1994.
11. Fountzilas G, Athanassiades A, Giannakakis T et al: A phase II study of Paclitaxel in advanced brease cancer resistant to anthracyclines. Eur J Cancer 32A: 47-51, 1996.
12. Chevallier B, Fumoleau P, Kerbrat P et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the EORTC-CSG. J Clin Oncol 13: 314-322, 1995.
13. Gianni L, Munzone E, Capri G et al: Paclitaxel by 3 hour infusion in combination with bolus Doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence finding study. J Clin Oncol 13: 2688-2699, 1995.
14. Dombernowsky P, Boesgaard M, Anderson E et al: Doxorubicin plus Paclitaxel in advanced breast cancer. Semin Oncol 24(suppl 12): S17-15-8, 1997.
15. Luck HJ, Thomssen C, Du Bois A et al: Metastatic breast cancer: Experience with the combination Paclitaxel plus Epirubicin. Oncology 12: 36-39, 1998.
16. Conte PF, Gennari A, Salvadori B et al: Paclitaxel plus Epirubicin in advanced breast cancer. Oncology 12: 40-44, 1998.
17. Matteis A, Nuzzo F, D'Aiuto G et al: Docetaxel plus Epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast. Cancer 94(4): 895-901, 2002.
18. Nabholtz JM, Senn HJ, Bezwoda WR et al: Taxotere versus Mitomycin C + Vinblastine in patients with metastatic breast cancer who have failed anthracycline containing regimen. J Clin Oncol 17(5): 1413-1424, 1999.
19. Milla-Santos A, Milla L, Rallo L et al: High dose Epirubicin plus Docetaxel at standard dose with Lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 24(2): 138-142, 2001.
20. Wenzel C, Locker G, Schmidinger M et al: Combined analysis of two phase II trials in patients with primary and advanced breast cancer with Epidoxorubicin and Docetaxel + granulocyte colony stimulating factor. Anti-Cancer Drugs 13: 67-74, 2002.
21. Fisher B, Bryant J, Wolmark N et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.